Biotechnology News and Research

RSS

New technique enhances understanding of chromatin organization

Researchers at the University of California San Diego Center for Epigenomics (C4E) have developed a new technique, called Droplet Hi-C, that allows scientists to rapidly determine chromatin organization, the arrangement of genetic material within cells.

18 Oct 2024

Ubiquigent partners with Alleo Labs to advance DUB-targeting therapies

Ubiquigent Limited (“Ubiquigent”), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced a strategic partnership with Alleo Labs Corp. (“Alleo”), a pioneer in using artificial intelligence (AI) to develop new therapeutics for neurological diseases.

18 Oct 2024

Brazil-Italy joint lab focuses on Alzheimer’s drug development

A self-proclaimed Brazil-Italy collaboration enthusiast, researcher Laura Bolognesi created the B2AlzD2 Joint Lab at the Department of Pharmacy and Biotechnology of the Università di Bologna (UNIBO), the first Brazil-Bologna joint laboratory dedicated to the development of new drugs for the treatment of Alzheimer's disease.

17 Oct 2024

Nuclera closes $75 million USD financing

Nuclera, the biotechnology company accelerating protein expression and purification workflows through its benchtop protein system, today announced it has completed a USD $75 million financing round (circa £57 million).

16 Oct 2024

Alleo and Ubiquigent enter AI-driven strategic partnership to accelerate DUB-focused drug discovery

From Ubiquigent Limited 16 Oct 2024

Case Western Reserve University receives grant to investigate AML treatment for veterans

With a new four-year, $1.3 million grant from the U.S. Department of Veterans Affairs, researchers at Case Western Reserve University are investigating a new approach to treat Acute Myeloid Leukemia (AML) in military Veterans.

15 Oct 2024

De novo antibody protein sequencing reveals novel functional and neutralizing antibodies post-SARS-CoV-2 vaccination

Rapid Novor has published a study that highlights the power of combining de novo antibody protein sequencing with conventional proteomics to uncover functional and neutralizing antibodies in human plasma following SARS-CoV-2 vaccination.

From Rapid Novor Inc 14 Oct 2024

Calluna Pharma appoints Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Independent Chair of the Board

Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the appointments of Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Chair of the Board.

From Calluna Pharma 14 Oct 2024

AI model LucaProt uncovers 251,000 new RNA viruses, revealing hidden diversity worldwide

Researchers developed an AI model, LucaProt, that uncovered over 251,000 new RNA virus species, expanding our understanding of the RNA virosphere across global ecosystems.

13 Oct 2024

New computational pipeline revolutionizes personalized cancer vaccine design

Ludwig Cancer Research scientists have developed a full, start-to-finish computational pipeline that integrates multiple molecular and genetic analyses of tumors and the specific molecular targets of T cells and harnesses artificial intelligence algorithms to use its output to design personalized cancer vaccines for patients.

12 Oct 2024

Your bathroom is a hidden haven of untapped viral biodiversity

A study reveals unique viral communities in toothbrush and showerhead biofilms, highlighting their role in microbial interactions and human health implications.

10 Oct 2024

Study uncovers mechanism of MX protein in fighting HIV-1 and herpes simplex virus

A group of researchers led by Xavier Saelens and Sven Eyckerman at the VIB-UGent Center for Medical Biotechnology discovered how a protein linked to the human immune system wards off HIV-1 and herpes simplex virus-1 by assembling structures in the cell that lure in these viruses and then trap them or even take them apart.

9 Oct 2024

Researchers discover potential therapeutic approach for triple negative breast cancer

Triple negative breast cancer (TNBC) remains the most aggressive and deadly type of breast cancer, but new findings from cancer researchers at Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, are pointing the way toward therapeutic strategies that could be tested in clinical trials in the future.

9 Oct 2024

Dual immunotherapy plus chemotherapy shows promise for specific lung cancer patients

Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more likely to benefit from adding the immunotherapy tremelimumab to a combination of durvalumab plus chemotherapy to overcome treatment resistance typically seen in this patient population.

9 Oct 2024

USC's Keck School of Medicine partners with StemCardia to advance heart failure treatment

The Keck School of Medicine of USC has launched a strategic collaboration with StemCardia, a biotechnology company, founded by a Keck School of Medicine faculty member, that develops cellular and genetic therapies to address heart failure.

8 Oct 2024

Ingenza announces move to purpose-built facilities to expand fermentation and research capacity

Ingenza – a world-leading contract research, development and manufacturing organisation (CRDMO) and technology accelerator – is delighted to announce its plans to relocate to the Moubray Building at Edinburgh Technopole, part of Pioneer Group. Following a detailed strategic review, the company has embarked on the creation of a multi-million pound facility to help drive its ambitious growth plans. The purpose-built premises will more than double Ingenza’s current footprint to approximately 25,000 square feet, expanding its fermentation and research facilities.

From Ingenza Ltd 7 Oct 2024

Biotechnology News and Research

New technique enhances understanding of chromatin organization

Ubiquigent partners with Alleo Labs to advance DUB-targeting therapies

Brazil-Italy joint lab focuses on Alzheimer’s drug development

Nuclera closes $75 million USD financing

Alleo and Ubiquigent enter AI-driven strategic partnership to accelerate DUB-focused drug discovery

Case Western Reserve University receives grant to investigate AML treatment for veterans

De novo antibody protein sequencing reveals novel functional and neutralizing antibodies post-SARS-CoV-2 vaccination

Calluna Pharma appoints Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Independent Chair of the Board

AI model LucaProt uncovers 251,000 new RNA viruses, revealing hidden diversity worldwide

New computational pipeline revolutionizes personalized cancer vaccine design

Your bathroom is a hidden haven of untapped viral biodiversity

Study uncovers mechanism of MX protein in fighting HIV-1 and herpes simplex virus

Researchers discover potential therapeutic approach for triple negative breast cancer

Dual immunotherapy plus chemotherapy shows promise for specific lung cancer patients

USC's Keck School of Medicine partners with StemCardia to advance heart failure treatment

Ingenza announces move to purpose-built facilities to expand fermentation and research capacity

Engineered E. coli shows promise in cancer immunotherapy

New humanized mouse models created to study COVID-19

Survey reveals strong public backing for ending animal testing in scientific research

The World Vaccine Congress returns to Barcelona, Spain

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News